II. Mechanism
- Biogenic Amine Hypothesis
- Depression is associated with decreased monoamine (Serotonin, Norepinephrine and Dopamine) neurotransmission
- Antidepressants that increase synaptic Neurotransmitter concentrations appear to improve Major Depression
- Delayed Antidepressant effects may be related to postsynaptic monoamine receptor downregulation
- In contrast, mania occurs when there is excessive monoamine neurotransmission
III. Types
- See Medical Management of Depression
-
Serotonin Norepinephrine Reuptake Inhibitors (SNRI)
- Tricyclic Antidepressants
- Tertiary amines: Amitriptyline (Elavil)
- Secondary amines: Nortriptyline (Pamelor)
- Other
- Tetracyclic: rarely use
- Tricyclic Antidepressants
- Serotonin Norepinephrine Reuptake Inhibitors (SNRI)
-
Selective Serotonin Reuptake Inhibitors (SSRI)
- Paroxetine (Paxil)
- Fluoxetine (Prozac)
- Sertraline (Zoloft)
- Fluvoxamine (Luvox)
- Citalopram (Celexa)
- Escitalopram (Lexapro)
- Vortioxetine (Brintellix)
- Norepinephrine Dopamine Reuptake Inhibitor (NDRI)
- Serotonin Antagonist and Reuptake Inhibitor (SARI)
- Norepinephrine Antagonist Serotonin Antagonist (NASA)
- Monoamine Oxidase Inhibitor (MAO Inhibitor)
IV. Efficacy
- Number Needed to Treat for significant improvement of Major Depression
V. Management
VI. Adverse Effects
VII. Complications
VIII. Resources: Patient Education
- Information from your Family Doctor